Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs

被引:69
作者
Fossati, Lina [1 ]
Dechaume, Rachel [1 ]
Hardillier, Emmanuel [1 ]
Chevillon, Delphine [1 ]
Prevost, Colette [1 ]
Bolze, Sebastien [1 ]
Maubon, Nathalie [1 ]
机构
[1] Labs Fournier, Preclin Candidate Select Unit, F-21121 Daix, France
关键词
Caco-2; cells; absorption assay; FaSSIF; transport; lipophilic acid drugs;
D O I
10.1016/j.ijpharm.2008.04.034
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The most commonly used method to assess intestinal permeability is the measurement of compound flux across a Caco-2 cells monolayer by using Hanks balanced salt solution (HBSS)-like buffers. Nevertheless, lipophilic acid drugs are poorly or not at all soluble in these types of buffers and their adsorption on the transwell plate is commonly observed. To reduce adsorption and increase solubility, permeability assays need to be developed in conditions other than classic conditions for lipophilic compounds. The best model to increase recovery of lipophilic compounds was determined as fasted state simulated intestinal fluid (FaSSIF) in the apical compartment and HBSS with 1% bovine serum albumin (BSA) in basolateral compartment. This model allows a correlation between absorption on Caco-2 cells and absorbed fraction in humans. For 35 compounds, only 2 outliers were observed in the Caco-2 assay using the FaSSIF model. These two outliers were the same outlier compounds as those observed with a classic Caco-2 method. Furthermore, a permeability assay of Pgp substrates evidenced efflux transport in both models and addition of a Pgp inhibitor suppressed Pgp efflux transport. FaSSIF in the apical compartment and HBSS with 1 % BSA in the basolateral compartment is the model of choice to predict in vivo absorption for lipophilic acid drugs. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:148 / 155
页数:8
相关论文
共 39 条
[21]   Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2 [J].
Ingels, FM ;
Augustijns, PF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (08) :1545-1558
[22]   Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes [J].
Kansy, M ;
Senner, F ;
Gubernator, K .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (07) :1007-1010
[23]   TRANSPORT OF CELIPROLOL ACROSS HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS - MEDIATION OF SECRETION BY MULTIPLE TRANSPORTERS INCLUDING P-GLYCOPROTEIN [J].
KARLSSON, J ;
KUO, SM ;
ZIEMNIAK, J ;
ARTURSSON, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (03) :1009-1016
[24]   Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2 [J].
Krishna, G ;
Chen, KWJ ;
Lin, CC ;
Nomeir, AA .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 222 (01) :77-89
[25]   IMIPRAMINE SERUM-PROTEIN BINDING IN HEALTHY-SUBJECTS [J].
KRISTENSEN, CB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 34 (05) :689-694
[26]  
Lau YY, 2004, DRUG METAB DISPOS, V32, P937
[27]   Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].
Lipinski, CA ;
Lombardo, F ;
Dominy, BW ;
Feeney, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25
[28]  
LISALO E, 1977, CLIN PHARMACOKINET, V2, P1
[29]   Exploring the role of different drug transport routes in permeability screening [J].
Matsson, P ;
Bergström, CAS ;
Nagahara, N ;
Tavelin, S ;
Norinder, U ;
Artursson, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (02) :604-613
[30]   Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR [J].
Maubon, Nathalie ;
Le Vee, Marc ;
Fossati, Lina ;
Audry, Mathilde ;
Le Ferrec, Eric ;
Bolze, Sebastien ;
Fardel, Olivier .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 (06) :659-663